BioX產研院賀林院士人工智能團隊為貝康醫療(02170.HK)賦能
為響應國家“產學研”深度融合的號召，實現優勢資源的整合和協同發展，2021年3月6日，蘇州貝康醫療股份有限公司(“貝康醫療”；股份代號：02170.HK)與蘇州BioX生命智能產業研究院(“BioX產研院”)賀林院士團隊簽署科技成果轉化協議，貝康醫療董事長與BioX產研院賀林院士出席了簽約儀式。
BioX產研院是中國首個以生命科學與臨牀遺傳方向為主的人工智能研究和產業轉化平台。據瞭解，BioX產研院聯合國家級醫學中心合作開發的“聾病遺傳諮詢與干預決策系統”可以通過人工智能為200餘種耳聾亞型遺傳病提供遺傳諮詢，並且干預診療決策，幫助解決耳科醫師面對複雜及海量的臨牀數據卻無法獲取其中潛在的疾病變化規律及精準遺傳諮詢建議的難題。2017年7月初，山東某婦女兒童醫院傳來新生兒的啼哭聲，患有耳聾的李女士(化名)歷經坎坷，終於迎來了自己健康的寶寶。這是該醫院首例通過PGT技術成功阻斷MITF基因雜合突變造成的Waardenburg綜合徵2A型耳聾的新生兒，由該醫院遺傳實驗室與賀林院士BioX產研院合力完成。BioX產研院的人工智能平台可以為遺傳病的診斷提供智能輔助決策支持，貝康醫療的PGT技術可在胚胎階段對遺傳病進行阻斷，雙方的合作將為遺傳病的診療與阻斷開啟創新產業新篇章，將幫助中國龐大的遺傳病患者以及致病基因攜帶者健康生育下一代，對國家的出生缺陷預防和人口健康戰略有着重大意義。
貝康醫療作為中國第一家生殖領域基因產業上市公司，致力於高通量測序技術在生育健康領域的研發和臨牀應用，是具備從技術研發、註冊報證、量產銷售為一體的完整的產業化平台。此次與BioX產研院賀林院士團隊達成戰略合作，將加速貝康醫療在遺傳病人工智能這一創新性領域的研發和產業轉化，為廣大的遺傳病患者提供創新的解決方案，拓寬輔助生殖產業充足的發展空間為貝康醫療產業佈局賦能，有助於雙方未來共同構建完整的輔助生殖產業生態，為推動中國輔助生殖技術的發展和國家及民族的優生事業貢獻力量！
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
